Celecoxib works by targeting the cyclooxygenase-2 enzyme, or COX2, which helps create the compounds that promote tumor growth, called prostaglandins. Animal studies conducted by the researchers revealed a daily dose of celecoxib slowed tumor growth significantly when compared to controls.
“Our study shows that COX2 inhibitors do have an effect on the tumor cells,” said study author William Guerrant, PhD. “They also have an impact on inflammatory responses that play a role in tumor growth.”
According to Dr. Guerrant, the effects of celecoxib may be even stronger in different types of cancer, based on the drug’s effect on inflammation.
To access the full study in Cancer Research, click here.
More articles on cancer care:
Early lung cancer screening improves survival rate more than 70%
Obama administration to host cancer moonshot summit
Key to making cancer more vulnerable to chemo lies with enzyme, researchers say
